J&J Highlights Spravato Remission Data to Drive TRD Growth
Esketamine, marketed by Johnson & Johnson as Spravato, has evolved from a niche add-on therapy into a primary monotherapy for treatment-resistant depression (TRD), with sales reaching $1.7 billion in 2024. Recent data presented at Psych Congress Elevate suggests that long-term remission rates for the drug may be more durable than previously documented in clinical literature, … Read more